United States of America based
MentiNova’s primary strategy is to use L-DOPA, the drug that is currently clinically approved for another indication and repurpose it for the treatment of L-Dopa Induced Dyskinesia in patients with Parkinson’s disease.
TechnologiesPharmaceutical and Drug Discovery
No pipelines published yet
No services posted yet